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University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, GermanyIntroduction: Disease-causing mutations in the protocadherin FAT1 have been recently described both in
patients with a glomerulotubular nephropathy and in patients with a syndromic nephropathy.
Methods: We identified 4 patients with FAT1-associated disease, performed clinical and genetic charac-
terization, and compared our findings to the previously published patients. Patient-derived primary urinary
epithelial cells were analyzed by quantitative polymerase chain reaction (qPCR) and immunoblotting to
identify possible alterations in Hippo signaling.
Results: Here we expand the spectrum of FAT1-associated disease with the identification of novel FAT1
mutations in 4 patients from 3 families (homozygous truncating variants in 3, compound heterozygous
missense variants in 1 patient). All patients show an ophthalmologic phenotype together with heteroge-
neous renal phenotypes ranging from normal renal function to early-onset end-stage kidney failure.
Molecular analysis of primary urine-derived urinary renal epithelial cells revealed alterations in the Hippo
signaling cascade with a decreased phosphorylation of both the core kinase MST and the downstream
effector YAP. Consistently, we found a transcriptional upregulation of bona fide YAP target genes.
Conclusion: A comprehensive review of the here identified patients and those previously published in-
dicates a highly diverse phenotype in patients with missense mutations but a more uniform and better
recognizable phenotype in the patients with truncating mutations. Altered Hippo signaling and de-
repressed YAP activity might be novel contributing factors to the pathomechanism in FAT1-associated
renal disease.
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genic disorders is a powerful and effective approach to
gain deeper insights in underlying pathogenic mecha-
nisms of renal disease. This is the prerequisite to ulti-
mately develop specific therapeutic strategies to
improve the treatment of these genetic diseases.
Affected proteins in genetic kidney diseases show a
huge variety of different expression patterns and mo-
lecular functions. Subsequently, phenotypes can range
from an isolated kidney pathology with only 1 specific
cell type affected (e.g., podocytes in NPHS1-associated
congenital nephrotic syndrome1) to a syndromicKidney International Reports (2021) 6, 1368–1378
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(e.g., autosomal dominant or recessive polycystic kid-
ney disease (ADPKD, ARPKD), or nephronophthisis
(NPH) and nephronophthisis-related ciliopathies).2 As
to the kidney, the disease-causing phenotype is often
restricted to 1 distinct population of epithelial cells
and leads to pathologies, for example, in either podo-
cytes or tubular epithelial cells in specific segments of
the nephron. Interestingly, mutations in the gene
encoding for the giant protocadherin FAT1 have been
identified in a subset of patients, with very heteroge-
neous phenotypes displaying isolated kidney disease
in some and multisystemic disorders in other cases.3–7
This kidney disease has been characterized as a glomer-
ulotubular nephropathy because both podocytes and
tubular cells are affected.5 Consistently, podocyte-
specific loss of FAT1 in mice leads to severe glomerular
disease,5 whereas loss of FAT1 in zebrafish causes cyst
formation in the pronephros which is ameliorated by
depletion of the Hippo effector Yap1.8 Interestingly, so-
matic mutations in FAT1 have been identified in
numerous tumor diseases and, consistent with the
observation in zebrafish,8 FAT1 has been shown to
be a potent regulator of Hippo signaling,9–12 a well-
established tumor-suppressor pathway. The Hippo
pathway has also been shown to be associated to
several kidney diseases,8,13–22 with evidence for both
overactivation and inactivation of Hippo signaling as
possible pathomechanisms.
We here report 4 patients from 3 families with
FAT1-associated syndromic nephropathy caused by
novel mutations that have been identified within the
framework of our clinical research unit (CRU329) dur-
ing the last 12 months. In addition, we present first
evidence that loss of FAT1 leads to dysregulation of the
Hippo pathway.PATIENTS AND METHODS
Patients
All patients were analyzed within an interdisciplinary
approach of our clinical research unit (CRU329). The
study was approved by the ethics committee of the
University Hospital Cologne, Germany (15-215). DNA
samples were obtained with written informed consent
from their guardians, and clinical and biochemical data
were collected retrospectively from medical charts.
Genetic Analysis
A custom gene panel consisting of 122 genes that are
associated with monogenic forms of proteinuria, as well
as other nephropathies with possible concomitant
proteinuria, was used (CRU329 Nephropathy Plus
Proteinuria Gene Panel; see Supplementary Table S1).Kidney International Reports (2021) 6, 1368–1378Whole exome sequencing was performed using the
Agilent SureSelect Human All Exom V7 enrichment
(Agilent Technologies Inc., Santa Clara, CA) followed
by next-generation sequencing on an Illumina HiSeq
4000 sequencing platform (Illumina, San Diego, CA).
TruSight One gene panel sequencing was performed on
an Illumina HiSeq 2500 sequencing platform. WES and
gene panel data analysis and filtering of variants were
carried out using the exome and genome analysis
pipeline “Varbank2, varpipe v.3.3” of the Cologne
Center for Genomics (University of Cologne). Variants
were classified in accordance with the ACMG standards
and guidelines for the interpretation of sequence
variants.23
Ophthalmologic Examination
Ophthalmologic examination comprised refraction,
best-corrected visual acuity (BCVA), anterior segment
examination, funduscopy with dilated pupil and
fundus photography, cycloplegic refraction, and an
orthoptic examination. The orthoptic examination
included measurement of binocular functions with
Bagolini striated glasses test, Lang test, and evaluation
of oculomotor findings such as smooth pursuit and
saccades. Strabismus was examined by prism-cover test
and by alternating cover test with prism at near and far
fixation.
Isolation and Culture of Patient-Derived Primary
Urine-Derived Renal Epithelial Cells
The protocol for the generation of primary urinary
epithelial cells was performed as previously
described.24 Urine-derived epithelial cells were
cultured from patients 2 and 3 and from 6 healthy
controls. Briefly, the urine collected was transferred in
1 or more 50-ml tubes and centrifuged at 400  g for 10
minutes at room temperature. The pellets were washed
in wash buffer (1X phosphate-buffered saline þ 100 U/
ml penicillin þ 100 mg/ml streptomycin þ 500 ng/ml
amphotericin B) and centrifuged at 200  g for 10
minutes at room temperature. After that, the pellets
were resuspended in 2 ml of Dulbecco’s modified Ea-
gle’s medium (DMEM)–nutrient mixture F-12 ham
(Sigma D6421; Sigma-Aldrich, St. Louis, MO) contain-
ing 10% fetal bovine serum, 1% GlutaMAX, 100 U/ml
penicillin, 100 mg/ml streptomycin, 500 ng/ml ampho-
tericin B, REGM renal epithelial cell growth medium
SingleQuots Kit supplements (Lonza CC-4127; Lonza,
Basel, Switzerland) and transferred in a 12-well plate,
previously coated with 0.1% sterile gelatin for 30 mi-
nutes at 37 C. The plates were then incubated at 37 C
in the presence of 5% CO2, and the first colonies were
visible after 4 to 5 days. Once colonies were visible, the
cells were switched to proliferation medium (1:11369
TRANSLATIONAL RESEARCH F Fabretti et al.: Hippo dysregulation in FAT1 nephropathymixture from renal epithelial and mesenchymal cells
medium). The renal epithelial medium was purchased
(CC-3190 þ Supplements; Lonza). The mesenchymal
cell medium was prepared with DMEM with high
glucose (Gibco, Waltham, MA) containing 10% fetal
bovine serum, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 1% nonessential amino acid solution (Gibco), 5
ng/ml fibroblast growth factor–basic (PeproTech,
Rocky Hill, NJ), 5 ng/ml platelet-derived growth
factor–AB (PeproTech) and 5 ng/ml epidermal growth
factor (PeproTech). When the cells reached a con-
fluency of 70% to 80%, they were passaged using
TrypsinLE (Gibco).
Quantitative Real-Time PCR
The primary urine-derived renal epithelial cells were
harvested and frozen at –80 C in TRI Reagent (Sigma).
RNA was extracted with Direct-zol RNA Miniprep kit
(Zymo Research, Irvine, CA) following manufacturer
instructions and cDNA was reverse transcribed using a
high-capacity cDNA reverse transcription kit (Thermo
Fisher Scientific, Waltham, MA) according to manu-
facturer instructions. Quantitative real-time PCR was
performed on a QuantStudio 12K Flex systemcycler
(Thermo Fisher Scientific) using 2 ng of reverse-
transcribed RNA per well and TaqMan Gene Expres-
sion Master Mix (Thermo Fisher Scientific) according to
manufacturer instructions. The probe-based assays
used are listed in Supplementary Table S2.
The relative quantity was calculated using the DDCt
method. Briefly, the expression of each gene was
normalized vs the amplification of either HPRT,
GAPDH, or POLR2A, calculating the DCt. The relative
quantity was calculated using as reference the average
DCt of all 5 healthy controls. Relative quantities were
then transformed in log2 and analyzed for significance
using t test (GraphPad Prism 8; GraphPad Software
Inc., San Diego, CA).
Immunoblotting
Whole protein lysates were prepared from primary
urine-derived renal epithelial cells resuspending cell
pellets in 1 sodium dodecyl sulfate (SDS) sample
buffer and boiling at 95 C for 5 minutes. Proteins were
separated by SDS polyacrylamide gel electrophoresis.
After transfer onto a polyvinylidene fluoride mem-
brane, and blocking in 5% bovine serum albumin, the
membranes were stained with anti phospho-Mst1
(Thr183) / Mst2 (Thr180), anti-MST1, anti-GAPDH,
anti-phospho-YAP (Ser127), anti-YAP, and anti-CDC42
(Cell Signaling Technology, Inc., Danvers, MA, cata-
log nos. 3681, 3682, 5174, 13008, 14074; and BD Bio-
sciences, Franklin Lakes, NJ, catalog no. 610928). The
signal was visualized using enhanced1370chemiluminescence after incubation of the membranes
with secondary antibodies conjugated to horseradish
peroxidase. Images were acquired with a Fusion Solo S
(Vilber Lourmat Germany GmbH, Eberhardzell, Ger-
many). Densitometric analysis was performed using the
software Image Studio, version 5.2 (LI-COR Biosciences
GmbH, Hamburg, Germany).
Systematic Literature Review
A systematic literature review on patients with muta-
tions in the FAT1 gene was performed. The genotypes
and phenotypes identified in this study were discussed
in relation to the previously described patients.
RESULTS
Genetic Data
Patient 1 (*2006) is the offspring of consanguineous
parents (Figure 1a). By gene panel analysis, a novel
homozygous nonsense variant (c.5648T>A) in exon 10
of the FAT1 gene was identified. This variant results in
a premature stop codon at position 1883 (p.Leu1883*)
(Figure 1b). Segregation analysis confirmed the variant
in a heterozygous state in both healthy parents. The
homozygous stop mutation was also identified in his
younger sister (patient 2, *2015). The variant was ab-
sent from the genome aggregation database (gnomAD,
last accessed in December 2020; Table 1).
In patient 3, gene panel analysis identified the ho-
mozygous frameshift variant c.8446_8447dupGC in
exon 10 of the FAT1 gene (p.Phe2817Hisfs*13). This
variant has not been described before and was not
found in the gnomAD database. Segregation analysis
confirmed the variant in a heterozygous state in both
consanguineous parents. In patients 1 to 3, no other
causative mutation was identified in the gene panel
analysis.
Patient 4 is the son of nonconsanguineous partners
and had previously received comprehensive genetic
testing with karyotyping, array comparative genomic
hybridization, targeted Sanger sequencing of the genes
LAMB2, LAMC1, PLCE1, WT1, and SMARCAL1 and
TruSight One gene panel sequencing, which all yielded
unremarkable results. The most recent gene panel
analysis identified 2 missense variants in the FAT1
gene, later confirmed to be in a compound-
heterozygous state: c.2563G>A (p.Gly855Arg) in
exon 2 and c.5539G>A (p.Val1847Ile) in exon 10.
Because both variants were classified as variants of
unknown significance, a trio exome (both parents and
the patient) analysis was performed. This analysis
confirmed the compound-heterozygosity for the afore-
mentioned FAT1 variants, but identified no de novo
variants in the patient. Biallelic variants in only 4 other
OMIM annotated genes (RLF, ASAP3, DNAH14, andKidney International Reports (2021) 6, 1368–1378
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Figure 1. Genetic and clinical overview of the 4 patients with FAT1-associated disease. (a) Pedigrees of the 3 families. (b) Schematic view of the
FAT1 protein domains. The FAT1 protein consists of 33 cadherin domains (CA), 1 laminin G domain (LamG), 5 epidermal growth factor–like
domains (E), a calcium-binding domain (C) and the transmembrane domain (TM). Mutations previously described are labeled in black, novel
mutations identified in this study are labeled in red. Truncating mutations are indicated above the protein scheme, missense mutations below
the protein scheme. (c) Bilateral ptosis, highly arched eyebrows, and ultrasonography of the hypodysplastic right kidney of patient 1 and typical
eye phenotype and feet syndactyly of patient 2. (d) Kidney biopsy in patient 3 showed low glomerular density and glomerular hypertrophy (300
mm). Syndactyly was surgically resolved in patient 3. (e) Highly arched eyebrows in patient 4 (left), anterior segment changes: micropupil,
shallow anterior chamber, and trophic corneal ulcer (middle) OD; kidney biopsy in patient 4 showed diffuse mesangial sclerosis (DMS). hom,
homozygous; het, heterozygous.
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Table 1. Detected FAT1 variants in 4 patients from 3 families
Patient, sex, age at
investigation
Ethnic







Patient 1, male, 14 yr Syrian Yes c.5648T>A (novel) 10 (homozygous) p.Leu1883*;
truncating
Patient 2, female, 5 yr, sister of
patient 1





























TRANSLATIONAL RESEARCH F Fabretti et al.: Hippo dysregulation in FAT1 nephropathyFBN3) were identified. Variants in RLF, ASAP3, and
DNAH14 have not been associated with a human dis-
ease phenotype so far. Two other compound-
heterozygous variants in FBN3—different from the
variants identified in patient 4—were previously re-
ported to segregate in a Chinese family in 2 siblings
affected with a Bardet-Biedl syndrome–associated dis-
ease without renal manifestation.25
The homozygous truncating mutations identified in
patients 1 to 3 and the compound heterozygous
missense mutations identified in patient 4 are located to
the cadherin repeats as outlined in the schematic of the
FAT1 protein (Figure 1b).
Clinical Presentation
The diagnosis of bilateral kidney hypodysplasia in
patient 1 was made at the age of 2 years. He was then
lost to follow-up and presented to the hospital with
acute appendicitis at the age of 9 years. Laboratory
evaluation revealed end-stage kidney disease, and
peritoneal dialysis was initiated immediately. TheTable 2. Synopsis of clinical findings in the patients with FAT1 mutations
Renal phenotype (age of onset)
Glomerular Other
Patient 1 Proteinuria (protein-creatinine:
3000 mg/g at ESKD)
Kidney hypodysplasia
ESKD/peritoneal dialysis (9 yr)
Living-donor KTx (11 yr) Micr
OD>
Patient 2 None None
Patient 3 Proteinuria (2 yr)
Glomerular hypertrophy, low
glomerular density (biopsy, 5 yr)
CKD 3 (10 yr)
Vesicoureteral reflux (6 mo),
spontaneous resolution at 2 yr of age
Patient 4 Nephrotic range proteinuria (6 yr)




Tubular ectasia and atrophy (biopsy, 6
yr)
Bilateral
CKD 3, chronic kidney disease stage 3; ESKD, end-stage kidney disease; KTx, kidney transpla
1372family then moved to Germany, and the patient
received a living donor kidney transplant from his
mother at the age of 11 years. At first clinical evalua-
tion in Germany, his protein-creatinine ratio was
elevated (3000 mg/g creatinine) with normal serum al-
bumin. Kidney graft function is optimal at current
investigation at the age of 14 years. Extrarenal symp-
toms are summarized in Table 2. His sister (patient 2)
was born in 2015 and presented with bilateral ptosis
(Figure 1c). Webbed toes (1 and 2) on the left foot were
revised surgically (Figure 1c). At current investigation
at the age of 5 years, there is no sign of proteinuria,
arterial hypertension, or decreased kidney function in
patient 2, and kidney ultrasonography shows no
abnormality.
Patient 3 presented at the age of 6 months with
recurrent urinary tract infections. A voiding cystour-
ethrography identified a bilateral vesicoureteral reflux
grade 3 that spontaneously resolved. At the age of 2
years, he was diagnosed with gross albuminuria (albu-





ophthalmos OD>OS with corneal opacity
OS, shallow anterior chamber, corectopia
Lower eyelid entropion (OS)
Visual impairment OD>OS
Syndactyly toes 2 and 3 (bilateral)
Brachytelephalangy digitus 3, left hand
Small pineal cyst
Elevation of transaminases and LDH (with
normal liver synthesis)






Recurrent pulmonary infections (first years
of life)
Bronchial asthma
Syndactyly toes 1 and 2, right foot and




neurotrophic keratopathy with trophic corneal










nt; LDH, lactate dehydrogenase; OD, oculus dexter; OS, oculus sinister.
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Figure 2. Dysregulation of Hippo signaling in patient-derived cells. Protein extracts from primary urine-derived renal epithelial cells (pURECs)
derived from patients 3 and 2 showed a decreased phosphorylation of the central Hippo kinase MST (MST1 pThr183/MST2 pThr180) in Western
blot, compared with cells derived from healthy individuals. (a) Western blot for MST1 and GAPDH was performed as loading control. (b) Protein
extracts from pURECs derived from patients 3 and 2 showed a significantly decreased phosphorylation on YAP Ser127 relative to the total
amount of YAP (P < 0.05) as shown in the Western and in the densitometric analysis. Bars show the SEM, and asterisks indicate statistical
significance: *P < 0.05 and ***P < 0.005. (c) qPCR performed on RNA derived from those cells confirmed the upregulation of the Hippo target
genes. Bars show the SEM, and statistical significance is indicated by asterisks as follows: *P < 0.05, **P < 0.01, ***P < 0.005, ****P < 0.001.
(d) Schematic representation of a possible pathomechanism in FAT1 nephropathy. In healthy individuals (upper panel), Hippo signaling is active:
the core kinase MST is phosphorylated, resulting in phosphorylation (and inactivation) of the effector proteins YAP and TAZ that are retained in
the cytoplasm. Loss of FAT1 results in inactivation of MST1/2 (decreased phosphorylation) and subsequent nuclear translocation of the active
(dephosphorylated) effector proteins YAP and TAZ, which act as transcriptional coactivators (lower panel). ns, not significant; SEM, standard
error of the mean.
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TRANSLATIONAL RESEARCH F Fabretti et al.: Hippo dysregulation in FAT1 nephropathyhypertension. Kidney function was normal. Therapy
with renin-angiotensin-aldosterone system inhibition
and b-blockers resulted in normalized blood pressure
and temporarily decreased proteinuria. Renal biopsy
was performed at the age of 5 years because of increased
albuminuria and showed severe glomerular hypertro-
phy and low glomerular density without any signs of
focal segmental glomerulosclerosis (Figure 1d). Since the
age of 10 years, patient 3 presents with nephrotic range
proteinuria and constantly decreasing kidney function
(current glomerular filtration rate [full age spectrum
equation] 50–60 ml/min). Syndactyly on both feet
(syndactyly toes 1þ2 right, 2þ3 left) was surgically
managed in early childhood. His eye phenotype includes
the typical bilateral ptosis and highly arched eyebrows.
Patient 4 presented at the age of 6 years to our unit
with nephrotic range proteinuria. Kidney biopsy
showed diffuse mesangial sclerosis and partial tubular
ectasia (Figure 1e). Renal function rapidly declined and
hemodialysis was initiated at the age of 7 years. The
patient received a cadaveric-donor kidney transplant at
the age of 9 years with good transplant function during
the last 12 years. Furthermore, the patient presents
with a severe psychomotor delay, deafness, and
recurrent epileptic seizures. His eye phenotype com-
prises anterior segment dysgenesis, bilateral micro-
coria, shallow anterior chamber, bilateral neurotrophic
keratopathy with trophic corneal ulcer and mild ptosis
(oculus dexter), bilateral high hyperopia, astigmatism,
and severely reduced visual acuity (Figure 1e). These
findings were consistent with microphthalmos, but
determination of the axial length was not possible
because of a lack in cooperation.
Analysis of Primary Urine-Derived Renal
Epithelial Cells From Patients
As FAT1 is known to regulate the Hippo signaling
pathway in the fly12 and in certain types of cancer
cells,9 we aimed to analyze possible alterations in Hippo
signaling activity in our patients and therefore isolated
primary urine-derived renal epithelial cells from the 2
patients with naïve kidneys (patients 2 and 3) and from
healthy controls. Protein lysates from those cells were
analyzed for expression and phosphorylation of com-
ponents of the Hippo pathway. This revealed decreased
phosphorylation of MST1/2, the ortholog of the Hippo
kinase in drosophila, in cells from the patients as
compared with those from healthy individuals
(Figure 2a). In addition, the phosphorylation of YAP as
the main downstream effector protein of Hippo
signaling was significantly decreased in patient cells as
compared with controls (Figure 2b). Consistent with
these data, target genes of the Hippo effector proteins
YAP and TAZ were significantly upregulated in the1374patient cells (Figure 2c). Quantitative PCR analysis also
revealed a significant upregulation of the Hippo
pathway core kinases on the mRNA level, whereas
expression of the Hippo effector protein YAP was not
altered (Supplementary Figure S1A). Interestingly, the
level of CDC42 mRNA did not significantly differ be-
tween patient and control cells, whereas immunoblot
analysis revealed a significant reduction of CDC42
protein levels in patient cells compared with healthy
individuals (Supplementary Figures S1B and S1C).
Literature Review
To date, 15 patients with FAT1 mutations have been
described, among these 11 with a truncating mutation
and 4 with homozygous or compound heterozygous
missense mutations.3–7 The mutations identified in
these patients are inserted in the gene scheme in
Figure 1b. Table 3 gives an overview on the clinical
characteristics of the patients published recently and of
the patients of this study.
DISCUSSION
We here expand the clinical spectrum of FAT1-associ-
ated disease by reporting 4 further patients from 3
families. A comprehensive review of the clinical phe-
notypes of these patients indicates a highly diverse
phenotype in patients with missense mutations but a
more uniform and therefore better recognizable pheno-
type in the patients with truncating mutations (Table 3):
Including the present study, the cohort of patients
with homozygous truncating mutations comprises 14
individuals from 8 families.3,6 The majority of these
patients presented with a specific ocular phenotype:
uni- or bilateral ptosis in nearly all patients (12/14),
uni- or bilateral coloboma in 9 patients (iris n¼3 and
retinal coloboma n¼6) and microphthalmia in 4 of the
14 patients. In addition, 11 of the 14 patients presented
with feet syndactyly. Intriguingly, the kidney pheno-
type, however, is quite variable, with absence of renal
manifestations in 6 of 14 patients, asymptomatic pro-
teinuria in 4 of 14 patients, nephrotic syndrome/pro-
teinuria plus chronic kidney disease in 3 of 14 and
bilateral renal hypodysplasia and end-stage kidney
disease in 1 of 14 patients. In summary, the co-
occurrence of ptosis (with or without coloboma) and
webbed toes seems to be highly suggestive of a FAT1-
truncating mutation, irrespective of the presence and
the kind of associated kidney disease.
The cohort of patients with FAT1 missense muta-
tions comprises only 5 patients: 3 patients described by
Gee et al.,5 1 described by Shojaei et al.,4 and patient 4
from this study. These patients do not display the
above-mentioned hallmark combination of an ocular
phenotype combined with feet syndactyly. However,Kidney International Reports (2021) 6, 1368–1378
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syndrome. Kidney biopsy performed in 3 of the pa-
tients yielded minimal-change nephrotic syndrome
(n¼1) and diffuse mesangial sclerosis (n¼2). The type of
extrarenal involvement in patients with missense mu-
tations seems to be highly variable: Gee et al. (2016)
reported 2 patients presenting with tumors (Ewing
sarcoma at the age of 13 years and Hodgkin lymphoma
at the age of 10 years) and 1 girl with hydrocephalus.5
There was no comment on extrarenal disease in the
Iranian case. The patient reported in this study (patient
4) suffers from a severe multisystemic disorder with
psychomotor delay, deafness, a severe eye phenotype,
and endocrinologic disease features (Table 2), which
prompted us to perform a trio exome analysis to look
for further variants to explain this severe phenotype.
After a careful analysis of the data, we are confident
that the mutation in the gene FAT1 is the most likely
explanation for the disease in patient 4 because of the
following reasons: The type of kidney disease with
evidence of diffuse mesangial sclerosis is in line with
the previously published patients. The mutation affects
one of the cadherin domains, which has been described
for other disease-causing missense mutations as well.
Comprehensive trio exome analysis did not identify
any alternative monogenic disorder or additional
pathogenic sequence variants that could contribute to
the complex phenotype. Still, we note that one of the
identified variants in this patient (c.2563G>A) has an
allele frequency of 0.21%, which is higher than ex-
pected in the healthy reference population, with 2
homozygous individuals listed in the gnomAD data-
base. A possible explanation for the hypothesized
disease-causing effect of this variant in our patient may
be a negative epistatic effect in conjunction with the
second variant in trans (c.5539G>A). Such epistatic
effects of common variants have been shown in other
monogenic nephropathies including NPHS2-associated
steroid-resistant nephrotic syndrome.26
A thorough phenotype review of the patients iden-
tified so far suggests a genotype-phenotype correlation,
with missense mutations being commonly associated
with nephrotic syndrome with variable extrarenal
disease. In contrast, truncating variants result in the
hallmark combination of ptosis and feet syndactyly
with variable kidney disease.
Interestingly, the kidney phenotype previously
described was a primarily glomerular phenotype with
proteinuria ranging from early-onset proteinuria with
ESKD in early childhood (e.g., patient 4) to proteinuria
with a slowly progressive chronic kidney disease (e.g.,
patient 3 or F3IV1 with focal segmental glomerulo-
sclerosis at the age of 20 years3) to asymptomatic pro-
teinuria. Tubular ectasia was found in biopsiesKidney International Reports (2021) 6, 1368–1378(without clinical evidence of a tubular disease) result-
ing in the classification as a glomerulotubular ne-
phropathy.5 Remarkably, 2 patients of our study also
presented with CAKUT features: patient 1 with bilat-
eral kidney hypodysplasia and patient 3 with bilateral
vesicoureteral reflux, which was also reported in 1
patient by Gee et al.5
Further genotype-phenotype studies will be defi-
nitely needed to understand the broad and heterogenic
spectrum of FAT1-associated disease, related to the
type of kidney disease but also to the variety of
extrarenal manifestations.
This study adds dysregulation of Hippo signaling to
the possible pathomechanisms underlying FAT1-associ-
ated disease. The giant protocadherin FAT1 was
described as a component of the glomerular slit dia-
phragm in rats as early as 200127 (at the time referred to as
FAT) and, shortly after, FAT1 was localized to the inter-
cellular junctions of podocytes.28 A conventional
knockout mouse of Fat1 showed perinatal lethality with
defect forebrain development, failure of eye develop-
ment, and foot process effacement.29 Podocyte-specific
deletion of Fat1 resulted in proteinuria and focal
segmental glomerulosclerosis at the age of 4 months with
abnormal foot process and slit-diaphragm development
already shortly after birth.5 The same study suggested
decreased cell adhesion andmigration in podocytes due to
reduced Rho-like small GTPase activity as one potential
mechanism involved in the pathogenesis of the FAT1
nephropathy.5 We here confirmed these data and show a
reduced level of CDC42 in urinary cells derived from our
patients (Supplementary Figure S1C). Interestingly, the
Rho-GTPase Cdc42 has been linked to Hippo signaling
since kidney-specific knock-out of Cdc42 results in
developmental defects that phenocopy loss of Yap.17,30
The authors therefore already speculated about a
possible role of Hippo signaling in FAT1-associated dis-
ease.5 Shortly after that study, Martin et al. reported that
FAT1 assembles a Hippo signaling complex, which re-
sults in the activation (phosphorylation) of theHippo core
kinases (MST, MOB, LATS) with subsequent repression
of YAP/TAZ transcriptional activity.9
We therefore decided to analyze Hippo signaling in our
patients harboring FAT1 mutations and used patient-
derived renal epithelial cells from the 2 patients with
naïve kidneys, one of them (patient 2) without any sign of
kidney disease and one (patient 3) with nephrotic range
proteinuria and chronic kidney disease stage 3. Intrigu-
ingly, Hippo signaling was dysregulated on several levels:
First, loss of FAT1 resulted in decreased phosphorylation
(inactivation) of MST as one of the Hippo core kinases.
Second, the main effector protein YAP was activated as
shown by reduced phosphorylation in patient cells. Third,
as a result of the inactivated Hippo signaling cascade and1375
Table 3. Synopsis of phenotypes associated with truncating and phenotypes associated with missense mutations in FAT1
Truncating Mutations
Study n Ocular features Feet syn-dactyly Kidney disease Intellectual disability
Lahrouchi et al. (2019) 10 9/10 8/10 5/10 3/10
pat. #1 (F1,IV:1) ptosis, coloboma, - proteinuria no
pat. #2 (F1,IV:3) ptosis bilateral - no
pat. #3 (F1,IV:5) ptosis, coloboma, micropthalmia bilateral proteinuria no
pat. #4 (F2,III:2) ptosis, coloboma unilateral none no
pat. #5 (F2,IV:1) ptosis, coloboma, microphtalmia unilateral none no
pat. #6 (F2,IV:3) ptosis, coloboma, microphtalmia bilateral none no
pat. #7 (F3,IV:1) - unilateral FSGS, proteinuria, CKD no
pat. #8 (F3,IV:3) ptosis, coloboma, microphtalmia unilateral proteinuria yes
pat. #9 (F4,II:2) ptosis bilateral none yes
pat. #10 (F4,II:2)/A4623, Gee et al (2016) ptosis - proteinuria; SRNS yes
Rossanti (2020) 1 0/1 0/1 1/1 0/1
one patient - - proteinuria no
Our study 3 3/3 3/3 2/3 0/3
patient #1 ptosis bilateral proteinuria, hypodysplasia, ESKD no
patient #2 ptosis unilateral none no
patient #3 ptosis bilateral proteinuria, VUR, CKD no
all 14 12/14






Gee (2016) 3 0/3 0/3 3/3 0/3
A3027 - - nephrotic syndrome, VUR, ESKD no
A789 - - nephrotic syndrome, MCNS no
A3507 - - nephrotic syndrome, DMS no
Serajpour (2019) 1 0/1 0/1 1/1 0/1
one patient - - nephrotic syndrome, SRNS -
Our study 1 1/1 0/1 1/1 1/1







CAKUT, congenital anomalies of the kidney and urinary tract; CKD, chronic kidney disease; DMS, diffuse mesangial sclerosis; ESKD, end-stage kidney disease; FSGS, focal segmental
glomerulosclerosis; MCNS, minimal change nephrotic syndrome; SRNS, steroid resistant nephrotic syndrome; VUR, vesicourethral reflux.
TRANSLATIONAL RESEARCH F Fabretti et al.: Hippo dysregulation in FAT1 nephropathyde-repressed YAP signaling, numerous YAP target genes
were significantly upregulated in the cells derived from
patients with FAT1-associated disease compared with
those from healthy controls. The potential pathomechan-
ism based on our findings is illustrated in Figure 2d.
Our observations are completely in line with the
above-mentioned data derived from cancer cells and
confirm the central role of Hippo signaling in kidney
development and disease. Besides the role of the Hippo
pathway in cystic kidney disease, recent studies also
demonstrated the importance of the pathway in podo-
cytes.8,16,31–35 Interestingly, both Hippo inactivation
and subsequent YAP activation as well as YAP inacti-
vation or depletion resulted in glomerular disease and a
very well-regulated balance seems to be indispensable
for normal podocyte function. It is therefore tempting
to speculate that dysregulation of Hippo signaling with
variable compensatory mechanisms in several kidney
cell types could explain the broad phenotypic spec-
trum of kidney disease in FAT1-associated disease. Of
note, the dysregulation of Hippo signaling could be1376used as a diagnostic measure in FAT1-associated dis-
ease by applying the Hippo qPCR panel used in this
study to urinary cells from patients suspected to harbor
mutations in FAT1. Intriguingly, the Hippo pathway
dysregulation was observed in both patients, in the one
without any kidney disease phenotype (patient 2) and
in the one with nephrotic range proteinuria and
chronic kidney disease (patient 3).
Although the Hippo signaling pathway might
represent a potential target of future therapeutic stra-
tegies, our findings have 1 additional implication.
Notably, none of the patients with truncating muta-
tions and complete loss of FAT1 presented with any
type of cancer. Whether the described tumors in 2
patients with missense mutations (Ewing sarcoma and
Hodgkin lymphoma) are associated with the loss of the
established tumor suppressor FAT1 and the consecu-
tive dysregulation of Hippo signaling remains unclear.
The role of the compensatory upregulation of other
Hippo components such as LATS, MST, MOB, and
Salvador (on mRNA level) as tumor suppressors andKidney International Reports (2021) 6, 1368–1378
F Fabretti et al.: Hippo dysregulation in FAT1 nephropathy TRANSLATIONAL RESEARCHpossible protective factors remains as speculative as the
question whether any type of tumor might have a more
aggressive course or a higher incidence in FAT1 pa-
tients. Thorough clinical follow-up of patients with
mutations in FAT1 is therefore indispensable and
might allow assessing the risk of tumors in the future.
In summary, this study extends the spectrum of mu-
tations in FAT1 and provides a detailed genotype-
phenotype correlation. In addition, our data provide ev-
idence that genetic alterations of a Hippo regulator are in a
prime position to cause defects inmultiple renal cell types,
which could explain the broad spectrum of renal pheno-
types observed in patients carrying a FAT1 mutation.
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